Patents by Inventor Véronique Bodo

Véronique Bodo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND FORMULATIONS FOR ADMINISTRATION OF THIOCARBAMATE DERIVIATIVES A2A INHIBITORS
    Publication number: 20230165863
    Abstract: The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors. Especially, the present invention relates to methods and formulations for treating and/or preventing cancers in a subject with a pharmaceutical composition comprising a thiocarbamate derivative as adenosine A2A receptor inhibitor. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancer.
    Type: Application
    Filed: April 16, 2021
    Publication date: June 1, 2023
    Inventors: Olivier De Henau, Veronique Bodo, Joanne Lager, Chiara Martinoli, Manfred Schneider
  • IL-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy
    Patent number: 11028441
    Abstract: The present invention concerns the use of IL-10 as a biological marker for predicting the responsiveness of a house dust mite allergic patient to house dust mite allergen immunotherapy.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: June 8, 2021
    Assignee: STALLERGENES
    Inventors: Laurent Mascarell, Véronique Bodo, Philippe Moingeon, Vincent Lombardi, Claire Gueguen
  • Markers of immune response
    Patent number: 11015221
    Abstract: The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 25, 2021
    Assignee: STALLERGENES
    Inventors: Laurent Mascarell, Claire Gueguen, Emmanuel Nony, Philippe Moingeon, Véronique Bodo
  • Sialylated fetuin-A as a marker of immunotherapy efficacy
    Patent number: 10884002
    Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: January 5, 2021
    Assignee: STALLERGENES
    Inventors: Vincent Lombardi, Noémie Caillot, Emmanuel Nony, Philippe Moingeon, Véronique Bodo, Julien Bouley
  • IL-10 AS A PREDICTIVE BIOMARKER OF RESPONSIVENESS TO HOUSE DUST MITE ALLERGEN IMMUNOTHERAPY
    Publication number: 20190024177
    Abstract: The present invention concerns the use of IL-10 as a biological marker for predicting the responsiveness of a house dust mite allergic patient to house dust mite allergen immunotherapy.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Applicant: STALLERGENES
    Inventors: Laurent MASCARELL, Véronique BODO, Philippe MOINGEON, Vincent LOMBARDI, Claire GUEGUEN
  • Biomarkers of immunotherapy efficacy
    Patent number: 10101341
    Abstract: The invention relates to proteins for use as markers for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: October 16, 2018
    Assignee: STALLERGENES
    Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Hélène Moussu, Karine Jain
  • SIALYLATED FETUIN-A AS A MARKER OF IMMUNOTHERAPY EFFICACY
    Publication number: 20170370946
    Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
    Type: Application
    Filed: November 23, 2015
    Publication date: December 28, 2017
    Inventors: Vincent LOMBARDI, Noémie CAILLOT, Emmanuel NONY, Philippe MOINGEON, Véronique BODO, Julien BOULEY
  • MARKERS OF IMMUNE RESPONSE
    Publication number: 20170233816
    Abstract: The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 17, 2017
    Inventors: Laurent MASCARELL, Claire GUEGUEN, Emmanuel NONY, Philippe MOINGEON, Véronique BODO
  • C1q as a therapeutic agent of allergy and/or asthma
    Publication number: 20160367631
    Abstract: The present invention concerns C1q for use for treating allergy and/or asthma. The invention also relates to a pharmaceutical composition comprising C1q and at least one allergen and to products comprising C1q and at least one allergen as a combined preparation for use for treating allergy and/or asthma.
    Type: Application
    Filed: July 2, 2014
    Publication date: December 22, 2016
    Applicant: STALLERGENES
    Inventors: Laurnt MASCARELL, Philippe MOINGEON, Sabi AIROUCHE, VERONIQUE BODO
  • BIOMARKERS OF IMMUNOTHERAPY EFFICACY
    Publication number: 20140112955
    Abstract: The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
    Type: Application
    Filed: April 6, 2012
    Publication date: April 24, 2014
    Applicant: STALLERGENES S.A.
    Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Héléne Moussu, Karine Jain